| Year |
Citation |
Score |
| 2020 |
Crump K, Crouch E, Zelterman D, Crump C, Haseman J. Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate. Toxicological Sciences. 175: 156-167. PMID 32191327 DOI: 10.1093/Toxsci/Kfaa039 |
0.301 |
|
| 2019 |
Abu-Khalaf M, Pierobon M, Denduluri N, Valdes-Albini F, Forero-Torres A, Clark A, Yung R, Mita M, Christensen S, Awerkamp K, Dunetz B, Murphy R, Hatzis C, Zelterman D, Liotta L, et al. Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot3-02-06 |
0.302 |
|
| 2016 |
Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. Biometrics. PMID 27669414 DOI: 10.1111/Biom.12590 |
0.304 |
|
| 2016 |
Stahl M, Podoltsev NA, DeVeaux M, Perreault S, Itzykson R, Ritchie EK, Sekeres MA, Fathi AT, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Brunner A, Roboz GJ, ... ... Zelterman D, et al. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort Blood. 128: 1063-1063. DOI: 10.1182/Blood.V128.22.1063.1063 |
0.308 |
|
| 2015 |
Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Research and Treatment. 150: 157-67. PMID 25687356 DOI: 10.1007/S10549-015-3292-8 |
0.311 |
|
| 2012 |
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, ... ... Zelterman D, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31: 4559-66. PMID 22139083 DOI: 10.1038/Onc.2011.539 |
0.314 |
|
| 2008 |
Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review International Journal of Colorectal Disease. 23: 139-145. PMID 17909820 DOI: 10.1007/S00384-007-0382-Z |
0.308 |
|
| Show low-probability matches. |